RESUMEN
AIMS: To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test. RESULTS: The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05). Second-phase insulin secretion was significantly increased only in the 1.25 mg/day group vs. placebo. Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05). There was no significant treatment effect on glucose effectiveness or insulin sensitivity. CONCLUSIONS: Fourteen weeks of treatment with liraglutide showed improvements in first- and second-phase insulin secretion, together with improvements in arginine-stimulated insulin secretion during hyperglycaemia.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Péptido 1 Similar al Glucagón/análogos & derivados , Hipoglucemiantes/uso terapéutico , Islotes Pancreáticos/metabolismo , Receptores de Glucagón/metabolismo , Péptido C/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Esquema de Medicación , Femenino , Péptido 1 Similar al Glucagón/uso terapéutico , Humanos , Incretinas/metabolismo , Resistencia a la Insulina , Liraglutida , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
BACKGROUND: Several population-based studies have reported blood glucose levels and blood pressure to be risk factors for the development of diabetic retinopathy. These studies were initiated more than two decades ago and may therefore reflect the treatment and population composition of a previous era, suggesting new studies of the present population with diabetes. AIM AND METHODS: This cross-section study included 656 people with type 1 diabetes and 328 with type 2 diabetes. Crude prevalence rates of proliferative diabetic retinopathy, clinically significant macular oedema and several specific retinal lesions were assessed, together with their association to a simplified and internationally approved retinal grading. RESULTS: The point prevalence of proliferative retinopathy was found to be 0.8% and 0.3% for type 1 and type 2 diabetes. Equivalent prevalence rates of clinically significant macular oedema were 7.9% and 12.8%, respectively. The most frequently occurring retinal manifestations increased in number until retinopathy level 3, and then decreased. CONCLUSION: The point prevalence of proliferative retinopathy is lower than that found in previous studies, whereas it is increased for clinically significant macular oedema. These data suggest different risk factors for these clinical entities.
Asunto(s)
Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 2/epidemiología , Retinopatía Diabética/epidemiología , Adolescente , Adulto , Anciano , Dinamarca/epidemiología , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Retinopatía Diabética/tratamiento farmacológico , Femenino , Humanos , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Vigilancia de la Población/métodos , Prevalencia , Estadísticas no ParamétricasRESUMEN
The objective of the study was to investigate the acute effect of a single very high dose of n-3 PUFA on coagulation and fibrinolysis. Forty healthy volunteers were randomized into two groups to receive either 20 grams of n-3 PUFA or 20 grams of n-6 PUFA as a single dose at 6 p.m. with their evening meal. Coagulation and fibrinolysis were evaluated in the fasting state at 8 a.m. the next morning and compared to values obtained at 8 a.m. the day before, when the participants were on their habitual diets. PAI-1 activity in plasma increased by a mean of 62% in subjects randomized to receive n-3 PUFA despite that no changes could be demonstrated in t-PA antigen levels. PAI-1 activity was unaltered in the 20 controls receiving n-6 PUFA. Plasma fibrinogen, coagulation factor VII, thrombin-antithrombin complexes and D-dimer did not significantly change after either supplement. The substantial increase in levels of PAI-1 activity in plasma after a single very high dose of n-3 PUFA may limit the usefulness of single very high doses of n-3 PUFA in acute clinical conditions.
Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Ácidos Grasos Omega-3/farmacología , Fibrinólisis/efectos de los fármacos , Inhibidor 1 de Activador Plasminogénico/análisis , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Activador de Tejido Plasminógeno/análisisRESUMEN
AIM: To explore the influence of a cilio-retinal artery on diabetic maculopathy. METHODS: In the county of North Jutland 481 diabetic subjects underwent examination for diabetic retinopathy during the period 1 June 2000 to 30 June 2001. A unilateral cilio-retinal artery was observed in 104 patients among which 29 revealed variation in right and left eye maculopathy. A bilateral cilio-retinal artery was observed in 15 diabetic subjects. The influence of a cilio-retinal artery on diabetic maculopathy was explored in a paired study. RESULTS: Diabetic maculopathy was found to be more severe in 26 of 29 eyes with a cilio-retinal artery (p<0.01) compared to eyes without it. The number of red dots (p<0.0001) and hard exudates (p=0.0002) were found to be significantly increased in eyes with a cilio-retinal artery, as also the number of eyes with central photocoagulation (p<0.05). In addition, clinically significant macular oedema was found to be significantly increased in eyes with a cilio-retinal artery compared to eyes without it (0.01
Asunto(s)
Arterias Ciliares/patología , Retinopatía Diabética/patología , Mácula Lútea/patología , Arteria Retiniana/patología , Adulto , Retinopatía Diabética/complicaciones , Humanos , Degeneración Macular/complicaciones , Degeneración Macular/patología , Edema Macular/complicaciones , Edema Macular/patología , Persona de Mediana EdadRESUMEN
Forty healthy volunteers were allocated in a double blind, randomized study to receive either 20 g of n-3 polyunsaturated fatty acids (PUFA) or 20 g of n-6 PUFA at their evening meal. The effect on plasma lipids and lipoproteins of this single dose of fish oil vs. corn oil was studied the next morning, 14 h after ingestion. Plasma triglycerides and very low density lipoprotein-cholesterol significantly decreased (33%) after n-3 PUFA (P < 0.001), and significantly (P < 0.01) more than after intake of n-6 PUFA. The decrease in plasma triglycerides after n-3 PUFA ingestion was more pronounced in subjects with higher baseline levels of triglycerides (P < 0.001). Total cholesterol decreased after both supplements, but did not differ between the supplements. Low density lipoprotein-cholesterol did not change, and high density lipoprotein-cholesterol significantly decreased in subjects given n-3 PUFA compared to baseline, but not when compared to subjects receiving n-6 PUFA. In conclusion, we have shown that a single very high dose of n-3 PUFA has a pronounced hypotriglyceridemic effect, which is directly related to the initial plasma level.
Asunto(s)
Grasas de la Dieta , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Insaturados/farmacología , Lipoproteínas/sangre , Triglicéridos/sangre , Adulto , Animales , Colesterol/sangre , HDL-Colesterol/sangre , LDL-Colesterol/sangre , VLDL-Colesterol/sangre , Método Doble Ciego , Femenino , Peces , Humanos , Masculino , Carne , Persona de Mediana Edad , Aceites , Valores de Referencia , Factores de Tiempo , VerdurasRESUMEN
The effects of dietary supplementation with n-3 fatty acids on the level of cytokines and complement activation in plasma from patients with rheumatoid arthritis were examined. Thirty-two patients with active rheumatoid arthritis were included in a 12-week double-blind, randomized study of dietary supplementation with n-3 fatty acids (3.6 g per day) or placebo. The cytokines were measured in plasma before and after treatment with fish oil or placebo. In general, cytokine values at the upper limits of the calculated normal areas were found. The Interleukin-1 beta concentration in plasma was reduced significantly after 12 weeks of dietary supplementation with fish oil (p < 0.03). No significant difference was observed in the placebo group. The tumour necrosis factor alpha activity in plasma did not change significantly (p = 0.167). No significant changes were observed in the degree of complement activation. The clinical status of the patients was improved in the fish oil group, but not in the placebo group, judged by Ritchie's articular index (p < 0.02). We conclude that dietary supplementation with n-3 fatty acids results in significantly reduced plasma IL-1 beta levels in patients with rheumatoid arthritis. Even though the cytokine levels were low, the anti-inflammatory effect of n-3 fatty acids could in part be explained by their ability to decrease cytokine production.
Asunto(s)
Artritis Reumatoide/sangre , Ácidos Grasos Omega-3/farmacología , Alimentos Fortificados , Interleucina-1/sangre , Artritis Reumatoide/fisiopatología , Activación de Complemento , Complemento C3/análisis , Método Doble Ciego , Ácidos Grasos Omega-3/administración & dosificación , Aceites de Pescado/administración & dosificación , Humanos , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Factor de Necrosis Tumoral alfa/análisisRESUMEN
In order to examine the short- and long term effects of basal/bolus insulin therapy on the metabolic regulation assessed by glycosylated haemoglobin (HbA1c) the first 201 patients in the diabetes out-patient clinic of the Section of Endocrinology, Department of Medicine, Aalborg Hospital, assigned for this treatment were prospectively studied. In all 201 patients a significant decrease in mean HbA1c value was observed after 21 months on multiple injection therapy (8.5% vs 8.1%; p < 0.001). The higher the HbA1c value on conventional therapy, the greater was the observed decrease in HbA1c following six months on basal/bolus therapy (r = 0.57, p < 0.001). According to an anonymous questionnaire completed by the first 140 patients six months after the start of multiple injection therapy, 97% of the patients preferred to continue with basal/bolus therapy with NovoPen, and 87% felt that they had achieved a better general condition and that the basal/bolus regime made their daily life easier. It is concluded that basal/bolus therapy with NovoPen may combine the attainment of improved metabolic control assessed by a decrease in mean HbA1c in many poorly regulated patients and the subjective experience of an improved quality of life.
Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Hemoglobina Glucada/análisis , Insulina/administración & dosificación , Adolescente , Adulto , Atención Ambulatoria , Dinamarca , Diabetes Mellitus Tipo 1/sangre , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inyecciones a Chorro , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Estudios Prospectivos , Factores de TiempoRESUMEN
The effect of dietary supplementation with n-3 polyunsaturated fatty acids (n-3 PUFA) on disease variables in patients with active rheumatoid arthritis was evaluated in a multicentre, randomized and double blind study. Fifty-one patients with active rheumatoid arthritis were included from three Danish hospital Departments of Rheumatology. The patients were allocated to 12 weeks of treatment with either six n-3 PUFA capsules (3.6 g) or six capsules with a fat composition averaging the Danish diet. Small but significant improvements in morning stiffness, joint tenderness and C-reactive protein were observed. There were no serious side-effects. Dietary supplementation with n-3 PUFA in patients with active rheumatoid arthritis has a modest effect on three out of eight disease variables, without effect on other traditional parameters for monitoring disease activity.
Asunto(s)
Artritis Reumatoide/dietoterapia , Ácidos Grasos Omega-3/administración & dosificación , Aceites de Pescado/administración & dosificación , Artritis Reumatoide/diagnóstico , Método Doble Ciego , Humanos , Pronóstico , Factores de TiempoAsunto(s)
Cardiomiopatías/prevención & control , Ácidos Grasos Omega-3/farmacología , Lipoproteínas/sangre , Adulto , Anciano , Angina de Pecho/sangre , Diabetes Mellitus/sangre , Relación Dosis-Respuesta a Droga , Ácidos Grasos Omega-3/administración & dosificación , Femenino , Humanos , Hiperlipidemias/sangre , Hipertensión/sangre , Cinética , Lipoproteína(a) , Masculino , Persona de Mediana EdadAsunto(s)
Periodo Posparto , Tiroiditis/etiología , Adulto , Femenino , Humanos , Embarazo , Hormonas Tiroideas/sangre , Tiroiditis/sangre , Tiroiditis/diagnóstico , Tirotropina/sangreAsunto(s)
Hipotiroidismo/enzimología , Anciano , Alanina Transaminasa/sangre , Fosfatasa Alcalina/sangre , Amilasas/sangre , Aspartato Aminotransferasas/sangre , Creatina Quinasa/sangre , Diagnóstico Diferencial , Humanos , Hipotiroidismo/diagnóstico , Isoenzimas , L-Lactato Deshidrogenasa/sangre , MasculinoRESUMEN
BACKGROUND: The influence of non-ophthalmic parameters on the prevalence of clinically significant macular oedema has not been unambiguously established. The present study was initiated with the aim of clarification. METHODS: This cross-sectional study comprised 656 type 1 and 328 type 2 diabetic subjects undergoing retinopathy screening in the county of North Jutland. The association between the presence of clinically significant macular oedema and blood pressure, HbA1c, BMI, age, onset of diabetes, duration of diabetes, blood-pressure-reducing medication, lipid-lowering medication, neuropathy and urinary albumin excretion was explored using multiple logistic regression analysis. RESULTS: We found no significant association between the presence of clinically significant macular oedema and any of the examined parameters in type 1 diabetic subjects. In type 2 diabetic subjects, the duration of diabetes, HbA1c, neuropathy and increased urinary albumin excretion was significantly associated with the presence of clinically significant macular oedema. CONCLUSIONS: The risk factors for clinically significant macular oedema differ in type 1 and type 2 diabetic subjects and can account only in part for this manifestation.
Asunto(s)
Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Retinopatía Diabética/epidemiología , Retinopatía Diabética/fisiopatología , Edema Macular/epidemiología , Edema Macular/fisiopatología , Adolescente , Adulto , Albuminuria/complicaciones , Albuminuria/etiología , Presión Sanguínea , Estudios Transversales , Dinamarca/epidemiología , Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 2/fisiopatología , Neuropatías Diabéticas/complicaciones , Retinopatía Diabética/diagnóstico , Hemoglobina Glucada , Humanos , Edema Macular/etiología , Tamizaje Masivo , Prevalencia , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de TiempoRESUMEN
Old sulphonylureas have been linked with adverse cardiovascular effects; however, data on the clinical implications are sparse. We examined the association between use of sulphonylureas and other antidiabetic drugs and the risk and case fatality rate (CFR) of myocardial infarction (MI) in a population-based case-control and follow-up study, respectively. A total of 6738 cases of first-time MI and 67,374 age- and gender-matched population controls were identified from the Hospital Discharge Registry and the Civil Registration System of North Jutland County, Denmark, in the period 1994 through 2002. Prescriptions for antidiabetic drugs before the index date were retrieved from a prescription database. We estimated odds ratios (ORs) of MI (case-control study) and 30-day CFR (follow-up study) associated with antidiabetic drug use adjusted for possible confounding factors and using nondiabetic subjects as the reference group. The risk of MI appeared higher among users of old sulphonylureas (adjusted OR, 2.07; 95% confidence interval (CI), 1.81-2.37) than among users of new sulphonylureas (adjusted OR, 1.36; 95% CI, 1.01-1.84). The adjusted ORs among users of nonsulphonylurea oral antidiabetic drugs, insulin, and patients with diabetes not receiving pharmacotherapy were 1.38 (95% CI, 0.90-2.11), 2.56 (95% CI, 2.16-3.03), and 3.51 (95% CI, 2.92-4.22), respectively. The overall 30-day CFR was 24.6%, but varied between 9.5% and 37.0% among the different categories. New sulphonylureas may be associated with a lower risk of MI than old sulphonylureas. Furthermore, the 30-day CFR may vary according to type of antidiabetic drug. These differences indicate the need for further examination of the cardiovascular safety of antidiabetic drugs.
Asunto(s)
Hipoglucemiantes/efectos adversos , Infarto del Miocardio/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Intervalos de Confianza , Dinamarca/epidemiología , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Hospitalización/estadística & datos numéricos , Humanos , Insulina/efectos adversos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Población , Pronóstico , Medición de Riesgo , Compuestos de Sulfonilurea/efectos adversosRESUMEN
Hypertension may eventually develop in response to chronic slight retention of sodium and expansion of the extracellular fluid volume, either due to intrinsic pathology or to neurohormonal influences of the kidneys. As almost half of all juvenile diabetic patients sooner or later will develop diabetic nephropathy and hypertension, data are discussed which tend to indicate that renal sodium metabolism is altered already early during the course of diabetes. Compared to healthy subjects the absolute total tubular sodium reabsorption is increased by approximately 30-40 per cent, as is the filtered sodium load. Insulin may stimulate sodium reabsorption in man through an effect on the distal nephron segment. However, by means of combined lithium and 51Cr-labelled EDTA clearances it has been clearly demonstrated that the excess sodium reabsorption in ambulatory insulin-dependent diabetics exclusively takes place in the proximal tubules, while the distal tubular function appears normal. In these studied patients the extracellular fluid volume was also significantly increased. The increased fractional sodium reabsorption of the proximal tubules remains unaffected by increasing duration of diabetes and is also demonstrable in patients with overt diabetic nephropathy. Glucose is reabsorbed in the early portion of the proximal tubules coupled to Na+ transport, utilizing a common carrier protein. An increased load of glucose will therefore be expected to induce an increase in the proximal tubular reabsorption rate of sodium and water, at least as long as the proximal tubular reabsorption capacity for glucose is not exceeded to a degree inducing significant osmotic diuresis. This deviation from normal in proximal renal sodium and fluid handling may be relevant to the development of hypertension in long-term insulin-dependent diabetes.
Asunto(s)
Diabetes Mellitus/fisiopatología , Hipertensión/fisiopatología , Riñón/metabolismo , Sodio/metabolismo , Complicaciones de la Diabetes , Humanos , Hipertensión/etiología , Túbulos Renales/fisiología , Túbulos Renales/fisiopatologíaRESUMEN
Serum beta 2-microglobulin was measured in 38 patients with thyroid diseases. Serum levels of beta 2-microglobulin were significantly increased in patients with untreated Graves' disease (median: 200 nmol l-1; P less than 0.0002), and in patients with untreated toxic adenomas (222 nmol l-1; P less than 0.0005) compared to 60 healthy control subjects (147 nmol l-1). Following antithyroid treatment of euthyroidism, serum beta 2-microglobulin decreased significantly in both Graves' disease (162 nmol l-1) and toxic adenomas (175 nmol l-1); values which were not significantly different from that of the control group. The level of serum beta 2-microglobulin in 12 patients with hypothyroidism was not different from that of the control group. However, in untreated hypothyroidism serum beta 2-microglobulin was positively correlated with serum thyroxine (T4) (rho = 0.69; P less than 0.05) and free thyroxine index (FT4I) (rho = 0.72; P less than 0.02). It is concluded that elevated levels of serum beta 2-microglobulin may reflect the increased metabolism in patients with thyrotoxicosis. Increased levels in active Graves' disease may also partly be caused by immunological activation.
Asunto(s)
Hipertiroidismo/sangre , Hipotiroidismo/sangre , Microglobulina beta-2/análisis , Adenoma/sangre , Adenoma/tratamiento farmacológico , Adulto , Anciano , Femenino , Enfermedad de Graves/sangre , Enfermedad de Graves/tratamiento farmacológico , Humanos , Hipertiroidismo/tratamiento farmacológico , Hipotiroidismo/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Tiroiditis Autoinmune/sangre , Tiroiditis Autoinmune/tratamiento farmacológicoRESUMEN
In a prospectively planned study of 591 Danish women thyroid dysfunction after delivery was found in 23 (3.9%). Seven women were hypothyroid and 16 were thyrotoxic. In seven of the thyrotoxic subjects a hypothyroid phase followed. Thyroid dysfunction was mostly transient with complete resolution within a year but persisted in three women (13%). Three months after delivery a positive titre of thyroid microsomal antibodies (TMAb) was found in 38 women (6.4%). Positive titres of TMAb were more often found in women with thyroid dysfunction than in those without (20/38 vs. 3/553). Maximal TMAb titres were seen 5-6 months after delivery and were associated with the occurrence of hypothyroidism. Postpartum thyroid dysfunction was found more often in women with a personal or family history of autoimmune thyroid disorder.
Asunto(s)
Hipotiroidismo/etiología , Trastornos Puerperales/etiología , Tiroiditis Autoinmune/etiología , Tirotoxicosis/etiología , Anticuerpos/análisis , Dinamarca , Femenino , Humanos , Hipotiroidismo/epidemiología , Hipotiroidismo/inmunología , Microsomas/inmunología , Embarazo , Estudios Prospectivos , Trastornos Puerperales/epidemiología , Trastornos Puerperales/inmunología , Glándula Tiroides/inmunología , Tiroiditis Autoinmune/epidemiología , Tiroiditis Autoinmune/genética , Tirotoxicosis/epidemiología , Tirotoxicosis/inmunologíaRESUMEN
Thirteen Danish women with postpartum thyroiditis were HLA-A, B, C and -DR typed. Nine of ten unrelated probands were DR4-positive which is significantly (corrected p = .01) different from the frequency (34.7%) of this antigen in unrelated controls.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Antígenos de Histocompatibilidad Clase II/análisis , Trastornos Puerperales/inmunología , Enfermedades de la Tiroides/inmunología , Femenino , Antígenos HLA/análisis , Antígeno HLA-DR4 , Humanos , Hipotiroidismo/inmunología , Embarazo , Tiroiditis/inmunologíaRESUMEN
The effect of dietary supplementation with 4 g of n-3 polyunsaturated fatty acids (PUFA) daily for 9 months on blood pressure, plasma lipids and lipoproteins, platelet function, coagulation and fibrinolysis was studied in 24 healthy volunteers. Each variable was determined before, after 6 weeks and 9 months of supplementation with n-3 PUFA, and 3 months after the supplementation period had ended. Systolic and diastolic blood pressure declined after intake of n-3 PUFAs. Plasma triglycerides were reduced, and there was a trend towards an increase in HDL-cholesterol after 9 months of supplementation, while total cholesterol, LDL-cholesterol and apolipoproteins A1 and B were unaltered. The bleeding time was increased, and plasma levels of von Willebrand factor decreased after 9 months supplementation with n-3 PUFA. Fibrinogen levels increased, while fibrinolysis was reduced after 9 months supplementation with n-3 PUFA. Overall, no clear benefit on lipid pattern and haemostasis was achieved with respect to development of coronary heart disease.